S4.5a A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan—top line results

OBJECTIVES: To determine whether, in addition to surgery, fosravuconazole (Fos) monotherapy of either 200 mg or 300 mg weekly was more effective [defined as complete cure at the End of Treatment (EOT; 52-week) visit] than the standard-of-care 12-month regimen of itraconazole (Itra) monotherapy, in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahal, Ahmed Hassan, Bakhiet, Sahar Mubarak, Mohamed, El Samani Wadaa, Ahmed, Eiman Siddig, Bakhiet, Osama El Hadi, Yousif, Abu Bakar Ahmed, Fahal, Lamis Ahmed, Alla, Hadel Yassir Atta, Razig, A Razig Osman A, Siddig, Emmanuel Edwar, Hassan, Omnia Babekir, Abdulla, Sahar A Rahman, Mohaemd, Amir Faroug, Jodda, Nagwa Adam, Bahar, Mustafa El Nour, Nyaoke, Borna A., Egondi, Thaddaeus, Oyieko, Peelen, Zijlstra, Eduard E., Strub-Wourgaft, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511563/
http://dx.doi.org/10.1093/mmy/myac072.S4.5a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511563/
http://dx.doi.org/10.1093/mmy/myac072.S4.5a

Ejemplares similares